Statements (61)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:immunotherapy
|
gptkbp:administered_by |
intravenous injection
|
gptkbp:approves |
gptkb:2001
gptkb:World_Health_Organization |
gptkbp:available_on |
intramuscular injection
oral tablet rectal suppository |
gptkbp:can_be_combined_with |
gptkb:lumefantrine
gptkb:mefloquine amodiaquine |
gptkbp:casnumber |
88495-63-0
|
gptkbp:chemical_formula |
C18 H26 O5
|
gptkbp:clinical_trial |
ongoing
|
gptkbp:composed_by |
chemical modification
semi-synthetic process |
gptkbp:developed_by |
gptkb:artemisinin
Chinese scientists |
gptkbp:duration |
3 days
5 days |
gptkbp:global_presence |
recommended for severe malaria
widely used in Africa widely used in Asia |
gptkbp:historical_use |
gptkb:traditional_medicine
ancient herbal remedies |
https://www.w3.org/2000/01/rdf-schema#label |
artesunate
|
gptkbp:interacts_with |
gptkb:warfarin
antiretrovirals anticonvulsants |
gptkbp:invention |
patented
generic available |
gptkbp:is_effective_against |
high efficacy against Plasmodium falciparum
rapid action reduces mortality in severe malaria |
gptkbp:is_recommended_by |
gptkb:WHO
|
gptkbp:marketed_as |
gptkb:artesunate_injection
|
gptkbp:mechanism_of_action |
inhibits parasite growth
|
gptkbp:produced_by |
gptkb:sweet_wormwood
|
gptkbp:provides_guidance_on |
recommended for children
included in malaria treatment guidelines recommended for pregnant women |
gptkbp:research_focus |
pharmacokinetics
efficacy studies combination therapies drug resistance safety profile |
gptkbp:side_effect |
gptkb:anemia
headache nausea allergic reactions vomiting diarrhea hypersensitivity thrombocytopenia |
gptkbp:storage |
room temperature
protected from light |
gptkbp:suitable_for |
severe renal impairment
severe liver impairment |
gptkbp:used_for |
treating malaria
|
gptkbp:bfsParent |
gptkb:Pentacarinat
gptkb:artemisinin-based_therapies |
gptkbp:bfsLayer |
7
|